Asad Haider
Stock Analyst at Goldman Sachs
(2.66)
# 2,010
Out of 5,122 analysts
14
Total ratings
66.67%
Success rate
16.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JNJ Johnson & Johnson | Maintains: Buy | $213 → $240 | $206.91 | +15.99% | 3 | Dec 19, 2025 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Neutral | $30 → $37 | $34.74 | +6.51% | 2 | Dec 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $51 → $57 | $54.21 | +5.15% | 2 | Dec 2, 2025 | |
| INVA Innoviva | Initiates: Sell | $17 | $19.90 | -14.57% | 1 | Sep 30, 2025 | |
| RPRX Royalty Pharma | Initiates: Buy | $42 | $38.99 | +7.72% | 1 | Sep 30, 2025 | |
| PCVX Vaxcyte | Initiates: Neutral | $38 | $45.41 | -16.32% | 1 | Sep 12, 2025 | |
| BNTX BioNTech SE | Initiates: Neutral | $110 | $95.28 | +15.45% | 1 | May 29, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Buy | $892 → $888 | $1,079.75 | -17.76% | 1 | Apr 8, 2025 | |
| ABBV AbbVie | Assumes: Neutral | $194 | $229.74 | -15.56% | 1 | Apr 8, 2025 | |
| PFE Pfizer | Downgrades: Neutral | $32 → $25 | $24.99 | +0.04% | 1 | Apr 8, 2025 |
Johnson & Johnson
Dec 19, 2025
Maintains: Buy
Price Target: $213 → $240
Current: $206.91
Upside: +15.99%
NewAmsterdam Pharma Company
Dec 2, 2025
Maintains: Neutral
Price Target: $30 → $37
Current: $34.74
Upside: +6.51%
Bristol-Myers Squibb Company
Dec 2, 2025
Maintains: Neutral
Price Target: $51 → $57
Current: $54.21
Upside: +5.15%
Innoviva
Sep 30, 2025
Initiates: Sell
Price Target: $17
Current: $19.90
Upside: -14.57%
Royalty Pharma
Sep 30, 2025
Initiates: Buy
Price Target: $42
Current: $38.99
Upside: +7.72%
Vaxcyte
Sep 12, 2025
Initiates: Neutral
Price Target: $38
Current: $45.41
Upside: -16.32%
BioNTech SE
May 29, 2025
Initiates: Neutral
Price Target: $110
Current: $95.28
Upside: +15.45%
Eli Lilly and Company
Apr 8, 2025
Upgrades: Buy
Price Target: $892 → $888
Current: $1,079.75
Upside: -17.76%
AbbVie
Apr 8, 2025
Assumes: Neutral
Price Target: $194
Current: $229.74
Upside: -15.56%
Pfizer
Apr 8, 2025
Downgrades: Neutral
Price Target: $32 → $25
Current: $24.99
Upside: +0.04%